Immuron has reported another quarter of steady sales expansion, underpinned by continued demand for its flagship product Travelan, as the company builds momentum across key international markets.
Immuron posts steady global gains as Travelan drives third quarter sales growth
April 19, 2026 Australian Biotech
Latest Video
New Stories
-
Australian company secures European approval for rare disease treatment
August 26, 2026 - - Latest News -
Australia cannot deliver meaningful change until the levers of power are rebalanced
August 26, 2026 - - Latest News -
Insurers warn cut could hit Australians most likely to need cancer care
August 25, 2026 - - Latest News -
Australian study finds maternal RSV vaccination offers strong protection for infants
August 25, 2026 - - Latest News -
Acrux brings experienced clinical leader aboard to advance testosterone program
August 24, 2026 - - Australian Biotech -
Avecho moves to deepen global partnering push as CBD insomnia program advances
August 24, 2026 - - Australian Biotech -
July recommendations across oncology, rare disease and chronic care
August 24, 2026 - - Latest News

